Malignant Mesothelioma Pipeline Activities and Therapeutic Assessment Covering Drug Profiles in 2017

Published on : Aug 14, 2017

Albany, New York, August 14, 2017: Mesothelioma is one of the least common types of cancer and its incidence rates still hover around 3000 new cases each in the U.S., according to the latest report from Centers for Disease Control and Prevention. However, scientific research and increased awareness are leading to earlier diagnoses, while improved and developing mesothelioma treatments are allowing patients to live longer than ever. To elaborate further, a pipeline study titled “Malignant Mesothelioma-Pipeline Insight, 2017” has been broadcasted to the wide repository of Market Research Hub (MRH). This research study aims to provide comprehensive insights of the ongoing therapeutic research and development across Malignant Mesothelioma.

Malignant mesothelioma is a rare, asbestos-related cancer that usually forms on the protective lining of the lungs and abdomen. It is generally caused by exposure to asbestos. Some major symptoms include shortness of breath, chest pain, and cough. It takes around 35 to 50 years for the symptoms to manifest. It has been analyzed that malignant mesothelioma is highly prevalent among geriatric population rather than other people. The drugs that are currently in use in the treatment do not show much response rates. The malignant mesothelioma treatment market requires drugs to increase the current survival rate. Nowadays, companies are focusing on collaborating with established research centers and other cancer drug manufacturers to develop drugs.

In the first part of the study, the report presents brief overview of Malignant Mesothelioma along with its pipeline therapeutics and pipeline products involved in this assessment. As per the study, global increase in prevalence rate of mesothelioma and growing healthcare spending on cancer care and treatment are significantly contributing to the growth of malignant mesothelioma treatment market. Malignant Mesothelioma treatment programs depend on many factors which mainly include the mapping of the stage at which the cancer is and the extent to which it has spread. The overall pipeline assessment has been done by monotherapy and combination therapy products, stage of development, RoA and molecule type for Malignant Mesothelioma.

The report further adds that with the advancement that the medical field has made over the years, diagnostic tools such as x-rays, MRI's, CT Scans have made it easier for mesothelioma to be detected, these tools have made the difference with mesothelioma treatment as early detection is vital to having a successful treatment and a higher survival rate.

Moreover, the report provides pipeline product profiles which contain product description, developmental activities, licensors & collaborators and chemical information. Also, report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Malignant Mesothelioma. Major pipeline molecules include durvalumab, tazemetostat, tremelimumab, nintedanib, ADI-PEG 20, and HSV 1716. Due to the rise in healthcare expenditure, therapeutic pipeline is anticipated to witness considerable growth in the malignant mesothelioma market in the near future.

Request a Sample with TOC in a PDF format :

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email :

Back To Top